Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maxim has had a target estimate of $12-$15 since late 2015.
Care to elaborate on those circumstantial clues? You got me curious
Another insty added 500 shares
https://fintel.io/so/us/avxl
Same source as you interpreted differently. Minimum of 600k and if it's more, they didn't say a maximum.
I think Anavex paid for the manufacturing of the drug and Rett will cover the rest. Hence Majority of the cost.
Or trials that target plaques will do that. 99% of Alz trials fail especially when 100% of them targeted the same thing.
Anavex continues to think outside the box.
Dr. Mac has been quoted as needing far less than thousands of participants, and more recent than April of last year.
Correct, they will run p2/3 and if the data is just as good as p2a/b, Goodbye P3, hello approval.
And this was a lawyer? Totally unprofessional on a official document.
Shorts will get their comeuppance with this stock one day. How exactly is the data meaningless? To use the pps as proof is no indication that it is, in fact, meaningless. As far as the prana trial, let me reference some DD WolfWayne did way back when he was an active member of the board.
post# 12694
You know what they say when you Assume Plato7?
Time will tell if you are correct, but many things to look forward to with this company.
Any particular reason as to why you value this 25% from its current valuation? Nothing but good data released and 2017 seems to be a busy year for this company? Trying to have a civil chat vs a shorters dream scenario.
I'd agree with that assumption. Missling shouldn't have to wait for the FDA to approve if other countries are willing to trial and approve first.
Doesn't have to be the same results. Better than placebo will be fine also.
Hmm. Doesn't look promising. So we will get readouts of p3 trial companies that still attack plaques.
CEO of Lilly said it's still a step forward for science, but what he should have said was that they will step ASIDE and let a risk taking company that won't target plaques have some mic time.
GLTA
What's the difference between a tute holding a small position say 2500 shares and an individual long that has 5000? I'm sure there are some here that are holding just as long as a tute or maybe even longer. Just curious
If p2/3 can replicate p2a/b, would we want a buyout offer? All we would need is a partner that could help guide from fast track approval to market. In the not to distant future, maybe 2 or 5 years, we could be BP ourselves. No sense in rushing to get a offer, when slow and steady results in a better pps. Just place your bets that you willing to lose, since nothing is a sure thing, and watch it grow. I like our chances of changing the treatment for ALZ.
Nice find. I fast-forwarded the video to 1:40 which is when Dr. Missling starts talking.
You forgot one.
It represents another foundation Anavex, the scam company, fooled. *wink*
Some may see it as insignificant. On the other hand, it gets a-273 p2 in Retts up and going and t-minus x months timeclock started. Its another small step checked off on Misslings checklist.
And Hess whom on facebook asked Rettsyndrome.org Where he can find more information about the funding granted for the Anavex Clinical trial.
Which Rettsyndrome.org replied with "more information will be released soon. Thanks for your interest."
https://www.facebook.com/RettSyndrome/
What is the thinking behind the pathogen hypothesis of Alzheimer’s?
Good read on this slow day.
http://www.news-medical.net/news/20170112/Could-pathogen-infection-really-lead-to-Alzheimere28099s.aspx
"So, in general the vast majority of the AD research field has focused and continues to focus on the pathology that occurs in the disease and not on the initiating triggers for this pathology."
"Also, clinical trials to obtain biomarkers based on infections as well as those for treatment using antivirals, antibacterials, and anti-inflammatory drugs are required to establish how treating for infection can potentially influence onset and/or progression of disease following early diagnosis."
"Is it likely that Alzheimer’s could be a treatable condition one day?
Yes, but we must identify the triggers of the disease first and focus on eradicating the triggering mechanisms, in this case infections, by using antibiotics, antivirals or other anti-infectives."
"Vaccines against amyloid and other naturally occurring entities in the body are probably not going to be useful in this disease and, to date, have failed in clinical trials."
I don't care too much about interviews as he smartly lets his trial do the talking. He gave one in the past, got burned and learned from it. Im willing to guess that once ph 2/3 for Alz and ph 2 for others start rolling, he will gladly start talking. Too much work, too little time given what? 6-8 employees. = )
I will have been in this stock 2 years come July. I'm not in a rush for the pps to be out of my reach. The slower we go, the more I can accumulate along the way. What matters is that we continue moving forward and keep presenting BP worthy data.
That is probably why Missling didn't entertain the idea of being bought out. People say it's because the drug isn't proven. IMO, if Anavex was for sale @7.05 ps, we would be snatched up real quick.
If in P2/3 safety continues to be spotless, what's the chances of a-273 being an otc bottle of pills like aspirin in the future? I mean, most prescribed drugs have side effects which is why a Dr. had to prescribe them, no?
I wouldn't call it a joke MC. BP had how many years and couldn't top the soc? Poor stubborn BP. I hope we don't get bought out.
Penn study finds evidence of AD neuropathology in post-mortem brains of LBD patients
Good Read. Here is the first paragraph
Patients who had a diagnosis of Parkinson's disease (PD) with dementia (PDD) or dementia with Lewy bodies (DLB) and had higher levels of Alzheimer's disease (AD) pathology in their donated post-mortem brains also had more severe symptoms of these Lewy body diseases (LBD) during their lives, compared to those whose brains had less AD pathology, according to research from the Perelman School of Medicine at the University of Pennsylvania. In particular, the degree of abnormal tau protein aggregations, indicative of AD, most strongly matched the clinical course of the LBD patients who showed evidence of dementia prior to their deaths, the team reports in The Lancet Neurology First Online, ahead of the January print edition.
http://www.news-medical.net/news/20170106/Penn-study-finds-evidence-of-AD-neuropathology-in-post-mortem-brainsc2a0of-LBD-patients.aspx
Good point about it being the patient decision to stop using a SOC approved drug. I thought I saw a video where Dr. Mac said the patients were given an option to stop using Donez or? Also, if ALL the patients didnt stop taking dual drugs, they can't say its a mono group yet.
It's 3 months down the road. Im just saying it'll happen when it'll happen. I'm a long and could care less WHEN the PR is, as long as we continue moving positively forward.
Hoping for a PR for something 3 months down the road is kinda useless.
Now waiting for news that p2/3 has 300 patients and will start or p2 in any of the other indications will begin is something to get excited about.
P2 success is most certainly not certified. The 2a/2b isn't either. It does ,however, provide a road map to create a much more likely successful ph 2/3.
Naive is BP who refuse to try or even accept another method of attacking the disease.
Naive is those that follow. Anavex is charting their own territory. Will they fail or succeed we will know in the coming year or two.
Naive is saying that they have THE CURE. I'm not saying that, I'm just stating the obvious that some seem to conveniently step over.
Naive is those that believe Anavex is not being manipulated and pps proves what the company is worth.
Finally, what the Market wants is more % of the float out of our retail investor hands.
IMO, we are in for a wild 2017.
Good luck to you LL53
Doesn't matter how much the N value is, as long as the FDA says its ok. Whats so difficult to see that what Anavex did with N=32 BP couldn't duplicate with N=(fill in the number)
Anavex has patients laughing, playing piano, going on walks with just 32, now 25, patients.
BP had thousands of patients and did even 1, just 1, do any of that?
case closed.
What about full selling rights to A-273 with Anavex getting a percent of all sales if it gets approved along with milestone payments?
And if Biogen offered a 1:1 buyout?
Wheres Adam when you need him
Major finding: Aducanumab 10 mg/kg was associated with a near-stabilization of the MMSE score over 24 months in 15 patients in an open-label extension of a phase Ib study.
They complain about our 32 patient trial now down to 25 and Biogen reports one group taking 10mg when theres only 15 patients? Open label too
Bottom line: I guess they don't have something worth paying someone money to spread fud about.
Exactly, and in reality the FDA could possibly stop the trial at any point after once data starts showing improvement for the placebo group. Exciting times ahead.
World wide rights of A-273 ? Id rather we go alone as long as possible
How about standard of care AS placebo for ph2/3 to silence critics once and for all. After 3 months, switch to a2-73 as compassionate use and watch what our drug will do compared to soc .
Happy new year
http://m.hawaiinewsnow.com/hawaiinewsnow/pm_/contentdetail.htm?contentguid=od:QuUNUyxE
Halfway down FDA wanted analysis of result so fare em though trial wasn't done . 82 of 121 was eligible for the result readout.
Sounds like Anavex one day soon.